Description: Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet. The company also offers accessory and consumable products for bioprinting and single-cell biology. The company was incorporated in 2012 and is based in Mölndal, Sweden.
Home Page: www.fluicell.com
Flöjelbergsgatan 8C
Mölndal,
431 37
Sweden
Phone:
46 7 62 08 33 54
Officers
| Name | Title |
|---|---|
| Ms. Carolina Trjulja | Chief Executive Officer |
| Mr. Gavin D. M. Jeffries | Co-Founder, CTO & Director |
| Mr. Joakim Wahlberg | Chief Financial Officer |
| Mr. Jonas Hannestad | Chief Marketing & Communications Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.1095 |
| Price-to-Book MRQ: | 1.0783 |
| Price-to-Sales TTM: | 17.0521 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |